Hayashi Ryunosuke, Ueno Nobuhiro, Watanabe Hiromu, Kobayashi Yu, Sakatani Aki, Takahashi Keitaro, Yuzawa Sayaka, Ando Katsuyoshi, Tani Chikayoshi, Kashima Shin, Shonaka Tatsuya, Moriichi Kentaro, Tanabe Hiroki, Tanino Mishie, Fujiya Mikihiro
Division of Gastroenterology, Department of Medicine, Asahikawa Medical University, Japan.
Department of General Medicine, Asahikawa Medical University Hospital, Japan.
Intern Med. 2025 May 1;64(9):1344-1349. doi: 10.2169/internalmedicine.4160-24. Epub 2024 Oct 4.
We herein present the case of a 30-year-old Japanese male patient with ulcerative colitis (UC) who was admitted to our hospital because of significant ascites. Upon evaluation, the patient was diagnosed with unresectable UC-associated colon cancer (UCAC), localized in the transverse colon. Using gene profiling of the tumor tissue, anti-epidermal growth factor receptor (EGFR) antibody combination chemotherapy was selected. Subsequently, the patient exhibited a temporary response to this regimen, with an enhancement in his quality of life and he was able to survive for 12 months. This case underscores the potential benefits of aggressive chemotherapy tailored to the gene profile in UCAC treatment, offering insights into potential avenues for improving the patient prognosis.
我们在此报告一例30岁的日本男性溃疡性结肠炎(UC)患者,因大量腹水入院。经评估,该患者被诊断为无法切除的UC相关结肠癌(UCAC),病变位于横结肠。通过对肿瘤组织进行基因分析,选择了抗表皮生长因子受体(EGFR)抗体联合化疗。随后,患者对该治疗方案出现了短暂反应,生活质量得到改善,并存活了12个月。该病例强调了针对UCAC治疗中基因谱定制的积极化疗的潜在益处,为改善患者预后的潜在途径提供了见解。